Skip to main content
Premium Trial:

Request an Annual Quote

Gregg Fergus, Anthony Burgess-Cassler, Dindyal Ramkissoon

Premium
Gregg Fergus has joined NimbleGen’s board of directors, the company said this week.
 
Fergus formerly was senior vice president of sales and global operations at Affymetrix and was chief commercial officer at Cellular Dynamics and Stem Cell Products.
 
Fergus also has consulted for Caden Biosciences and was an executive in residence at Baird Venture Partners.
 

 
Anthony Burgess-Cassler has been named senior scientist at QuantRx's Corporate Research Center in Portland, Ore., the firm said this week.
 
Burgess-Cassler joined QuantRx from Calypte Biomedical. He holds a BS in chemistry from ValparaisoUniversity in Indiana and a PhD in biochemistry from the University of Illinois-Urbana.
 

 
Dindyal Ramkissoon has been appointed vice president of sales and marketing of CombiMatrix Molecular Diagnostics, CMDX's parent CombiMatrix said this week.
 
Ramkissoon will be responsible for leading CMDX’s marketing initiatives for its molecular diagnostics business and for assembling CMDX’s national sales organization.
 
He previously held similar positions at Applied Spectral-Imaging, Cyberonics, and Applied Imaging. Ramkissoob holds a BS in biology from Winona State University in Minnesota.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.